A low dose of anti-thymocyte globulin A (ATG), an immunosuppressive, was able to preserve beta cells in patients with newly diagnosed Type 1 diabetes, according to new data released recently at the 2025 European Association for the Study of Diabetes (EASD) Meeting and published in The Lancet .

Type 1 diabetes is a disease where the immune system destroys insulin-producing beta cells in pancreatic islets. Type 1 diabetes is a chronic disease where patients rely on insulin and careful monitoring of blood glucose levels. It affects approximately 9.5 million people worldwide and about 2 million in the United States.

ATG is an immunosuppressant that works by blocking the immune cells that destroy beta cells. High-dose ATG is used after organ transplants to prevent rejection.

Previous res

See Full Page